- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Looking Ahead for the Management of Plaque Psoriasis
Author(s):
Drs Mark Lebwohl and Saakshi Khattri review recent advancements and emerging therapies in development for plaque psoriasis treatment.
This is a video synopsis of a discussion involving Mark Lebwohl, MD, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in Manhattan, New York, and Saakshi Khattri, MD, a board-certified dermatologist, rheumatologist, and internist at the same institution.
Dr. Khattri expresses excitement about upcoming developments in psoriasis treatment, particularly oral small molecules. She highlights ongoing research on a TYK2 inhibitor and an oral IL-23 peptide, both showing promising results in phase two trials. Additionally, an oral IL-17 molecule and a systemic nanobody for IL-17A and F are in development, addressing the need for more systemic treatment options in psoriasis.
Dr. Lebwohl shares his positive experience with the oral IL-23 peptide, emphasizing its efficacy despite initial skepticism about its bioavailability. He discusses the robust results of clinical trials, indicating significant improvements in psoriasis symptoms. The discussion extends to the potential of oral TNF inhibitors and the shift away from traditional biologics due to their superior efficacy and safety profiles.
Both panelists emphasize the importance of balancing efficacy and safety when discussing treatment options with patients. Dr. Khattri reassures patients about the safety profile of IL-23 blockers, contrasting them with older drugs like methotrexate. Dr. Lebwohl underscores the rapid response and safety of newer treatments like JAK inhibitors, highlighting their role in both dermatology and rheumatology.
In conclusion, the panelists highlight the transformative impact of upcoming oral therapies on psoriasis management, offering improved efficacy and safety compared to traditional treatments. They emphasize the need for ongoing research and patient education to optimize treatment outcomes in psoriasis.
Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.
